Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Company

WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1

Fineline Cube Apr 25, 2023

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...

Company Legal / IP

SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns

Fineline Cube Apr 25, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...

Company Deals

Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development

Fineline Cube Apr 25, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...

Company Drug

GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14

Fineline Cube Apr 24, 2023

The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...

Company Drug

Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan

Fineline Cube Apr 24, 2023

China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...

Company Deals

Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million

Fineline Cube Apr 24, 2023

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor

Fineline Cube Apr 24, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies

Fineline Cube Apr 24, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...

Company

YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 24, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...

Company

LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch

Fineline Cube Apr 23, 2023

China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...

Company Deals

Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT

Fineline Cube Apr 23, 2023

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...

Company Drug

Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC

Fineline Cube Apr 23, 2023

Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...

Hospital Policy / Regulatory

China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide

Fineline Cube Apr 23, 2023

The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...

Company Drug

ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent

Fineline Cube Apr 23, 2023

ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...

Company Deals

CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments

Fineline Cube Apr 23, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140...

Company Deals

PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange

Fineline Cube Apr 23, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates

Fineline Cube Apr 23, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD...

Posts pagination

1 … 491 492 493 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.